Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NimbuDerm
- Development stage
- Preclinical
- Lead developer
- Quick-Med Technologies
- Modality
- Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Implantable Hydrogels → Hydrogel Systems → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Topical
01
Overview
NimbuDerm is a novel antimicrobial copolymer developed by Quick-Med Technologies for use as a persistent hand sanitizer. Unlike traditional alcohol-based sanitizers that evaporate quickly and offer no residual activity, NimbuDerm is designed to provide rapid and sustained antimicrobial protection for up to eight hours following a single topical application. The technology utilizes a small molecule-based copolymer formulation to create a long-lasting barrier on the skin, aimed at improving hand hygiene compliance and reducing the transmission of pathogens in healthcare and consumer settings. It has achieved proof-of-principle as a safe and effective modality for infection prevention.
- Brand names
- NimbuDerm
Beyond the preview
Go deeper on NimbuDerm.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NimbuDerm.